Article

The Potential Use of Arsenic Trioxide in the Treatment of Systemic Lupus Erythematosus

2024-08-13

Abstract excerpt

Arsenic trioxide (ATO) is now part of the standard regimen for the treatment of newly diagnosed and relapsed acute promyelocytic leukaemia. The availability of an oral form of ATO has greatly reduced the incidence of cardiotoxicity as compared to intravenous administration. Increasing evidence suggests that ATO has anti-inflammatory properties that may be useful for the treatment of autoimmune diseases. These incl...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2fc43821-a483-5529-a607-8825e3c253b4
DOI: 10.20944/preprints202408.0864.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The Potential Use of Arsenic Trioxide in the Treatment of Systemic Lupus ErythematosusDOI 10.20944/preprints202408.0864.v1Read

Oxidative Stress Contributes to Inflammatory and Cellular Damage in Systemic Lupus Erythematosus: Cellular Markers and Molecular MechanismSemantic proximity Read

Molecular Targets of Arsenic Trioxide in Malignant CellsSemantic proximity Read

Treatment of Acute Promyelocytic LeukemiaSemantic proximity Read

Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity.Semantic proximity Read

The Role of the Oxidative State and Innate Immunity Mediated by TLR7 and TLR9 in Lupus NephritisSemantic proximity Read

Mesenchymal Stem Cell Therapy: Hope for Patients With Systemic Lupus Erythematosus.Semantic proximity Read

The Role of Glucocorticoids in Inflammatory Diseases.Semantic proximity Read

Supersulfides: A Promising Therapeutic Approach for Autoinflammatory DiseasesSemantic proximity Read

Safety, Pharmacokinetics, Biomarker Response, and Efficacy of E6742, a Dual Antagonist of Toll-Like Receptors 7 and 8, in a First-in-Patient, Randomized, Double-Blind, Phase 1/2 Study in Systemic Lupus ErythematosusSemantic proximity Read

Feraheme® suppresses immune function of human T lymphocytes through mitochondrial damage and mitoROS productionSemantic proximity Read

Treatment of acute promyelocytic leukaemia with <i>all-trans</i> retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapySemantic proximity Read

Quercetin ameliorates lupus symptoms by promoting the apoptosis of senescent Tfh cells via the Bcl-2 pathwaySemantic proximity Read